



This form, when completed, will be classified as 'For official use only'.
 For guidance on how your information will be treated by the TGA see: Treatment of information provided to the TGA at
<http://www.tga.gov.au/about/tga-information-to.htm>.

OTC medicine evaluation

Analytical validation summary

Analytical method number:	
Assay/identification (circle) of:	
Method type (eg. HPLC, GC, IR):	

Performance parameter	Results	Page no.	Met acceptance criteria Y/N		
Accuracy Typically determined at three concentrations over the range.	Concentration determined at (% of nominal)	Percentage recovery	RSD		
Precision Intermediate Repeatability	Variable assessed (e.g. analyst, equipment)	Number of replicates	Mean	RSD	
	N/A N/A				

Performance parameter	Results						Page no.	Met acceptance criteria Y/N	
Linearity/range	Concentration determined at (% of nominal)	%,	%,	%,	%,	%,	%		
	Correlation coefficient r^2								
	y-intercept (%)								
Specificity							Peaks interfering with the analyte (Y/N)		
Chromatograms to support the specificity of the method must be provided. Include the page numbers of the relevant supporting chromatograms.	Placebo/excipients								
	Other actives (state)								
	Related substances (state)								
	Other (state)								
Specificity Forced degradation		Y/N	If yes, state any relevant details (e.g. % decrease in recovery, stressing conditions)						
Forced degradation studies may not be necessary for active assays where known degradants have been used to establish specificity. Include the page numbers of the relevant supporting chromatograms.	Decreased recovery of the analyte after stressing.								
	New peaks formed.								
	Any interfering peaks.								
	Peak purity acceptable.								
Detection limit (LOD)									

Performance parameter	Results	Page no.	Met acceptance criteria Y/N
Quantitation limit (LOQ)			
Other (e.g. robustness, solution stability)			

Name			
Signature		Date	